Latest news
Lake Street Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $45 - MoomooMoomoo · Fri, 07 Aug 2026 19:23:23 GMTALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - StocktwitsStocktwits · Fri, 07 Aug 2026 18:10:26 GMTAligos Therapeutics, Inc. Q2 10-Q Filing: Financial Statements, Key Risks, and Company Overview 2026 - MinichartMinichart · Thu, 06 Aug 2026 22:30:00 GMTAligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 14:09:37 GMTAligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 12:13:00 GMTAligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 12:11:09 GMTAligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock TitanStock Titan · Thu, 06 Aug 2026 12:08:12 GMTAligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingViewTradingView · Thu, 06 Aug 2026 12:03:18 GMT